The role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer

Obstetrics and Gynecology

Volumn 117, Issue 3, 2011, Pages 742-746

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; MEMBRANE PROTEIN; MUC16 PROTEIN, HUMAN;

ABDOMINAL PAIN; BLOATING; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CYTOREDUCTIVE SURGERY; DIFFERENTIAL DIAGNOSIS; DISEASE DURATION; DISEASE SEVERITY; EARLY CANCER; EARLY DIAGNOSIS; GYNECOLOGIST; HIGH RISK POPULATION; HUMAN; OBSTETRICIAN GYNECOLOGIST; OVARY CARCINOMA; OVERALL SURVIVAL; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SURGEON; SURVIVAL RATE; TRANSVAGINAL ECHOGRAPHY; ARTICLE; BLOOD; FEMALE; GYNECOLOGY; MASS SCREENING; NEOPLASM; OVARY TUMOR; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; STANDARD;

CA-125 ANTIGEN; FEMALE; GYNECOLOGY; HUMANS; MASS SCREENING; MEMBRANE PROTEINS; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PHYSICIAN'S ROLE;

EID: 79954493924     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e31821477db     Document Type: Review

References (36)

1. Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med 2009;361:170-7.
2. Daniilidis A, Karagiannis V. Epithelial ovarian cancer. Risk factors, screening and the role of prophylactic oophorectomy. Hippokratia 2007;11:63-6. (Pubitemid 46879120)
3. Pavlik EJ, DePriest PD, Gallion HH, Ueland FR, Reedy MB, Kryscio RJ, et al. Ovarian volume related to age. Gynecol Oncol 2000;77:410-2. (Pubitemid 30368559)
4. DePriest PD, Gallion HH, Pavlik EJ, Kryscio RJ, van Nagell JR Jr. Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecol Oncol 1997; 65:408-14. (Pubitemid 27255979)
5. Sato S, Yokoyama Y, Sakamoto T, Futagami M, Saito Y. Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography. Cancer 2000;89:582-8. (Pubitemid 30640104)
6. Bourne TH, Campbell S, Reynolds KM, Whitehead MI, Hampson J, Royston P, et al. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. BMJ 1993;306:1025-9.
7. van Nagell JR Jr, DePriest PD, Reedy MB, Gallion HH, Ueland FR, Pavlik EJ, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 2000;77:350-6.
8. van Nagell JR Jr, DePriest PD, Ueland FR, DeSimone CP, Cooper AL, McDonald JM, et al. Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer 2007;109:1887-96.
9. Fishman DA, Cohen L, Blank SV, Shulman L, Singh D, Bozorgi K, et al. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol 2005;192:1214-21; discussion 1221-2.
10. Partridge E, Kreimer AR, Greenlee RT, Williams C, Xu JL, Church TR, et al. Results from four rounds of ovarian cancer screening in a randomized trial. PLCO Project Team. Obstet Gynecol 2009;113:775-82.
11. Hayashi H, Yaginuma Y, Kitamura S, Saitou Y, Miyamoto T, Komori H, et al. Bilateral oophorectomy in asymptomatic women over 50 years old selected by ovarian cancer screening. Gynecol Obstet Invest 1999;47:58-64. (Pubitemid 29026897)
12. Tabor A, Jensen FR, Bock JE, Hogdall CK. Feasibility study of a randomised trial of ovarian cancer screening. J Med Screen 1994;1:215-9.
13. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-7. (Pubitemid 13014028)
14. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989;4:1-12. (Pubitemid 19069900)
15. Woolas RP, Xu FJ, Jacobs IJ, Yu YH, Daly L, Berchuck A, et al. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst 1993;85:1748-51. (Pubitemid 23320845)
16. Einhorn N, Sjovall K, Knapp RC, Hall P, Scully RE, Bast RC Jr, et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol 1992;80:14-8.
17. Skates SJ, Menon U, MacDonald N, Rosenthal AN, Oram DH, Knapp RC, et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 2003;21:206s-10s.
18. Menon U, Skates SJ, Lewis S, Rosenthal AN, Rufford B, Sibley K, et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 2005;23:7919-26. (Pubitemid 46657391)
19. Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005;15(suppl 3):274-81. (Pubitemid 43096594)
20. Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, et al. Diagnostic markers for early detection of ovarian cancer [published errata appear in Clin Cancer Res 2008;14:5308; Clin Cancer Res 2008;14:7158]. Clin Cancer Res 2008;14:1065-72. (Pubitemid 351302552)
21. Greene MH, Feng Z, Gail MH. The importance of test positive predictive value in ovarian cancer screening. Clin Cancer Res 2008;14:7574; author reply 7577-9.
22. McIntosh M, Anderson G, Drescher C, Hanash S, Urban N, Brown P, et al. Ovarian cancer early detection claims are biased. Clin Cancer Res 2008;14:7574; author reply 7577-9.
23. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009;10:327-40.
24. National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian. V.1.2010. NCCN Clinical Practice Guidelines in Oncology. Fort Washington (PA): NCCN; 2010. Available at: http://www.nccn.org/ professionals/physician-gls/PDF/genetics-screening.pdf. Retrieved November 4, 2010.
25. Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999;353:1207-10. (Pubitemid 29168457)
26. Hogg R, Friedlander M. Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol 2004;22:1315-27. (Pubitemid 41079847)
27. van der Velde NM, Mourits MJ, Arts HJ, de Vries J, Leegte BK, Dijkhuis G, et al. Time to stop ovarian cancer screening in BRCA1/2 mutation carriers? Int J Cancer 2009;124: 919-23.
28. Gaarenstroom KN, van der Hiel B, Tollenaar RA, Vink GR, Jansen FW, van Asperen CJ, et al. Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study. Int J Gynecol Cancer 2006;16 (suppl 1):54-9.
29. Olivier RI, Lubsen-Brandsma MA, Verhoef S, van Beurden M. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol 2006;100:20-6. (Pubitemid 41815044)
30. Hereditary breast and ovarian cancer syndrome. ACOG Practice Bulletin No. 103. American College of Obstetricians and Gynecologists. Obstet Gynecol 2009;113:957-66.
31. Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer 2000;89:2068-75.
32. Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004;291:2705-12. (Pubitemid 38725419)
33. Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007;109:221-7. (Pubitemid 46106236)
34. Pavlik EJ, Saunders BA, Doran S, McHugh KW, Ueland FR, Desimone CP, et al. The search for meaning-symptoms and transvaginal sonography screening for ovarian cancer: predicting malignancy. Cancer 2009;115:3689-98.
35. Rossing MA, Wicklund KG, Cushing-Haugen KL, Weiss NS. Predictive value of symptoms for early detection of ovarian cancer. J Natl Cancer Inst 2010;102:222-9.
36. U.S. Food and Drug Administration. FDA clears a test for ovarian cancer: test can help identify potential malignancies, guide surgical decisions. Silver Spring (MD): FDA; 2009. Available at: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm182057.htm. Retrieved November 4, 2010.